Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Affiliations

• ¹ Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France. [email protected].
• ² Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000, Lille, France. [email protected].
• ³ Medical Oncology, Centre Léon Bérard, Lyon, France.
• ⁴ Medical Oncology, Paul Brousse University Hospital, Villejuif, France.
• ⁵ Medical Oncology, Gustave Roussy, Villejuif, France.
• ⁶ Gastroenterology, University Hospital, Poitiers, France.
• ⁷ Methodology and Biostatistics, Centre Oscar Lambret, Lille, France.
• ⁸ Medical Oncology, Clinique Sainte Anne, Strasbourg, France.
• ⁹ Medical Oncology, Hopital Privé des Côtes d'Armor, Plérin, France.
• ¹⁰ Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France.
• ¹¹ Clinical Research Unit, Centre Oscar Lambret, Lille, France.
• ¹² Gastroenterology, University Hospital, Saint Etienne, France.
• ¹³ Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France.